DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Average Rating of “Hold” from Brokerages

DiaSorin S.p.A. (OTCMKTS:DSRLF) has been given a consensus recommendation of “Hold” by the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company.

A number of research analysts recently commented on DSRLF shares. Zacks Research upgraded DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft downgraded shares of DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday, June 17th. UBS Group lowered shares of DiaSorin from a “buy” rating to a “neutral” rating in a report on Thursday, April 9th. BNP Paribas Exane cut shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research note on Tuesday, July 7th. Finally, Piper Sandler started coverage on shares of DiaSorin in a report on Thursday, June 11th. They set a “neutral” rating for the company.

DiaSorin Price Performance

Shares of OTCMKTS:DSRLF opened at $77.60 on Tuesday. DiaSorin has a 1-year low of $66.50 and a 1-year high of $100.00. The business’s 50 day moving average is $77.55 and its 200-day moving average is $76.52.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.